id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2024-D-4540-0001,FDA,FDA-2024-D-4540,Recommended Followup Testing for an Ames-Positive Drug (Active Ingredient) or Metabolite To Support First-in-Human Clinical Trials With Healthy Subjects; Draft Guidance for Industry; Availability,Notice,Notice of Availability,2024-11-27T05:00:00Z,2024,11,2024-11-27T05:00:00Z,,2024-11-27T15:40:10Z,2024-27796,0,0,090000648683a82d
FDA-2024-D-4540-0002,FDA,FDA-2024-D-4540,Recommended Follow-Up Testing for an Ames-Positive Drug (Active Ingredient) or Metabolite To Support First-in-Human Clinical Trials With Healthy Subjects; Guidance for Industry and Review Staff - Draft Guidance,Other,Guidance,2024-11-27T05:00:00Z,2024,11,2024-11-27T05:00:00Z,2025-02-26T04:59:59Z,2025-02-28T02:00:38Z,,1,0,090000648683b09f